Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

Research

JDRF-funded researcher wins prestigious award at international diabetes conference

Professor Maike Sander was celebrated for her research on pancreatic islet cells at the recent EASD conference in Sweden.
Breakthrough T1D profile picture
Kate Gerrard 11 October 2022

Maike Sander

Professor Maike Sander, a JDRF-funded researcher, has won the prestigious Albert Renold Prize at the recent EASD (European Association for the Study of Diabetes) conference.

Professor Sander said: “It’s a true honour to be recognised with this prize. I have been fortunate to work with outstanding trainees who really deserve the credit. Thank you also to all collaborators for their creativity and generous contributions.”

The prize was awarded at the latest EASD conference, which saw around 12,000 diabetes researchers, advocates and healthcare workers congregate in Sweden to share brand new developments in the field.

The Albert Renold Prize

This coveted prize is awarded each year to one researcher for their ‘outstanding achievement’ in studying a group of cells called pancreatic islets, where insulin-producing beta cells are found.

Out of the 16 prizes awarded in total, 13 of those have gone to researchers who were funded by JDRF at some point in their career. This shows that JDRF consistently funds research that is internationally recognised as being the very best.

Professor Sander’s type 1 diabetes research

Professor Sander is currently based in California, but will soon move to Berlin, Germany. Her team grows beta cells from human stem cells, and she gave an update on their projects in her Award Lecture at EASD.

Lab-grown beta cells don’t function as well as real human beta cells, meaning they don’t release enough insulin in response to glucose. Professor Sander delved into their genetics to understand why.

Comparing lab-grown to donor beta cells

The researchers used stem cells to grow pancreatic islets containing beta cells and compared them to human pancreatic islets from donors. They discovered that they were making an immature version of human beta cells found in fetuses, known as fetal beta cells. So, the next step was to figure out how to get these cells to mature into functioning adult beta cells.

Maturing beta cells

Professor Sander’s team also noticed that stress pathways were more active in beta cells from donors. The research team thinks that mild stress may help beta cells mature. Their next task is to test whether this works, and we look forward to hearing their results.

Adding blood supply

Pancreatic islets receive a large supply of blood to provide them with the nutrients and oxygen they need. In contrast, beta cells in the lab are made without blood vessels. So, Professor Sander’s team worked with bioengineers to grow pancreatic islets alongside blood vessels on a chip.

When they tested these beta cells’ response to glucose, they found they functioned better than islets they had grown without a blood supply. This demonstrates to other researchers the need to grow beta cells with connecting blood vessels.

Mimicking what happens in type 1

The lab’s next project will involve taking samples of blood and stem cells from people with type 1 and growing these into beta cells and immune cells in the lab. They will use these to mimic the immune attack that occurs in type 1 to better understand how it could be prevented and treated.

Related news

Read more
Scientist researcher woman in white coat using microscope in laboratory
Research
1 July 2025

New trial results show potential protection against kidney damage in young adults  

A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1

Read more
A woman researcher at work in a lab
Research
24 June 2025

Six-month clinical data shows engineered islets can exist without immunosuppression

New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.

Read more
Vertex Pharmaceuticals logo graphic
Research
23 June 2025

Vertex trial of Zimislecel cellular therapy enables ten of 12 participants to remain insulin independent

US-based company Vertex have published promising figures from their cell therapy trial, showing advancements in stem cell research.

Read more
Two older men at home reading type 1 diabetes information booklets.
Research
17 June 2025

Healthcare systems unprepared for rising number of older adults with T1D

We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.